Cart
sales@molnova.com
Nafimidone
CAS No. 64212-22-2
Nafimidone( —— )
Catalog No. M36202 CAS No. 64212-22-2
Nafimidone shows anticonvulsant activity in a rat model of amygdala epilepsy and can be used in the treatment of chronic intractable epilepsy.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 70 | In Stock |
|
| 10MG | 104 | In Stock |
|
| 25MG | 201 | In Stock |
|
| 50MG | 269 | In Stock |
|
| 100MG | 398 | In Stock |
|
| 200MG | 569 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameNafimidone
-
NoteResearch use only, not for human use.
-
Brief DescriptionNafimidone shows anticonvulsant activity in a rat model of amygdala epilepsy and can be used in the treatment of chronic intractable epilepsy.
-
DescriptionNafimidone shows anticonvulsant activity in a rat model of amygdala epilepsy and can be used in the treatment of chronic intractable epilepsy.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number64212-22-2
-
Formula Weight236.27
-
Molecular FormulaC15H12N2O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(CN1C=CN=C1)(=O)C2=CC3=C(C=C2)C=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
ZD-6888 Hydrochlorid...
ZD-6888 Hydrochloride, an angiotensin type 1 receptor antagonist, is used potentially for the treatment of hypertension.
-
Mizoribine
An immunosuppressive agent that inhibits the proliferation of lymphocytes selectively, via inhibition of IMPDH.Rheumatoid ArthritisApproved
-
Examorelin
Examorelin is an agonist of growth hormone-releasing factor (GHRF), and for the treatment of cardiac diseases.hexarelin treatment protected cardiac function in the chronic phase as evidenced by higher ejection fraction and fractional shortening, as well as lower lung weight/body weight and lung weight/tibial length ratios, compared with vehicle treatment.?
